Comments
Loading...

Monte Rosa Therapeutics Analyst Ratings

GLUENASDAQ
Logo brought to you by Benzinga Data
$4.92
At close: Jun 9 EDT
$4.92
0.000.00%
Pre-Market: 4:00 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$22.00
Lowest Price Target1
$10.00
Consensus Price Target1
$15.75

Monte Rosa Therapeutics Analyst Ratings and Price Targets | NASDAQ:GLUE | Benzinga

Monte Rosa Therapeutics Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Monte Rosa Therapeutics Corp from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Dec 24
2
1
Mar
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.7
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Wells Fargo
Wedbush
LifeSci Capital
Piper Sandler
JP Morgan

1calculated from analyst ratings

Analyst Ratings for Monte Rosa Therapeutics

Buy NowGet Alert
03/21/2025Buy NowWells Fargo
Derek Archila60%
$11 → $10MaintainsEqual-WeightGet Alert
03/21/2025Buy NowWedbush
Robert Driscoll45%
$15 → $17MaintainsOutperformGet Alert
03/12/2025Buy NowLifeSci Capital → $19Initiates → OutperformGet Alert
12/19/2024Buy NowWells Fargo
Derek Archila60%
$14 → $11DowngradeOverweight → Equal-WeightGet Alert
09/12/2024Buy NowWedbush
Robert Driscoll45%
$11 → $11ReiteratesOutperform → OutperformGet Alert
08/12/2024Buy NowWells Fargo
Derek Archila60%
$18 → $17MaintainsOverweightGet Alert
06/28/2024Buy NowPiper Sandler
Edward Tenthoff51%
$16 → $16ReiteratesOverweight → OverweightGet Alert
05/22/2024Buy NowWedbush
Robert Driscoll45%
$11 → $11ReiteratesOutperform → OutperformGet Alert
02/15/2024Buy NowWedbush
Robert Driscoll45%
→ $11Initiates → OutperformGet Alert
10/19/2023Buy NowJP Morgan
Eric Joseph44%
$31 → $11MaintainsOverweightGet Alert
08/11/2023Buy NowCredit Suisse
Richard Law48%
→ $11ReiteratesNeutral → NeutralGet Alert
05/12/2023Buy NowCredit Suisse
Richard Law48%
→ $11ReiteratesNeutral → NeutralGet Alert
03/17/2023Buy NowCredit Suisse
Richard Law48%
$12 → $11MaintainsNeutralGet Alert
01/03/2023Buy NowWells Fargo
Derek Archila60%
→ $19UpgradeEqual-Weight → OverweightGet Alert
10/13/2022Buy NowUBS
Eliana Merle46%
→ $22Initiates → BuyGet Alert
08/15/2022Buy NowJefferies
Kelly Shi44%
→ $20Initiates → BuyGet Alert

FAQ

Q

What is the target price for Monte Rosa Therapeutics (GLUE) stock?

A

The latest price target for Monte Rosa Therapeutics (NASDAQ:GLUE) was reported by Wells Fargo on March 21, 2025. The analyst firm set a price target for $10.00 expecting GLUE to rise to within 12 months (a possible 103.25% upside). 7 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Monte Rosa Therapeutics (GLUE)?

A

The latest analyst rating for Monte Rosa Therapeutics (NASDAQ:GLUE) was provided by Wells Fargo, and Monte Rosa Therapeutics maintained their equal-weight rating.

Q

When was the last upgrade for Monte Rosa Therapeutics (GLUE)?

A

The last upgrade for Monte Rosa Therapeutics Inc happened on January 3, 2023 when Wells Fargo raised their price target to $19. Wells Fargo previously had an equal-weight for Monte Rosa Therapeutics Inc.

Q

When was the last downgrade for Monte Rosa Therapeutics (GLUE)?

A

The last downgrade for Monte Rosa Therapeutics Inc happened on December 19, 2024 when Wells Fargo changed their price target from $14 to $11 for Monte Rosa Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Monte Rosa Therapeutics (GLUE)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Monte Rosa Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Monte Rosa Therapeutics was filed on March 21, 2025 so you should expect the next rating to be made available sometime around March 21, 2026.

Q

Is the Analyst Rating Monte Rosa Therapeutics (GLUE) correct?

A

While ratings are subjective and will change, the latest Monte Rosa Therapeutics (GLUE) rating was a maintained with a price target of $11.00 to $10.00. The current price Monte Rosa Therapeutics (GLUE) is trading at is $4.92, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch